Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on the development and commercialization of inhaled therapies for cardiopulmonary disease, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). - View it on GitHub